Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy), and tirzepatide (Mounjaro, Zepbound), which is a dual GIP/GLP-1 receptor agonist, influence blood sugar regulation and appetite
And yes, they can absolutely help with appetite suppression and short-term fat loss
Dose- and time-dependent increase in GH receptor expression in tendon fibroblasts, potentiating GH response via JAK2 phosphorylation (Kuo et al., 2018)
Who should avoid IV therapy
Landmark research published by Khavinson and colleagues demonstrated that Epithalon treatment resulted in statistically significant increases in telomerase activity and measurable telomere elongation in human fetal fibroblast cell lines, allowing cells to undergo more divisions beyond their normal Hayflick limit
Biotechnol 2017, 5